Effect of Chronic Hematologic Malignancies on In-Hospital Outcomes of Patients With ST-Segment Elevation Myocardial Infarction

      In view of hemorrhagic and prothrombotic tendencies, ST-segment elevation myocardial infarction (STEMI) patients with chronic hematologic malignancies (CHM) are felt to be at a higher risk and hence denied standard reperfusion strategies. In-hospital outcomes of CHM patients presenting with STEMI are unclear. The Nationwide Inpatient Sample data files from 2003 to 2014 were used to extract adult patients who presented with a primary diagnosis of STEMI. Patients who had a diagnosis of CHM defined as chronic myelogenous leukemia, chronic lymphocytic leukemia, essential thrombocythemia, polycythemia vera, chronic monocytic leukemia, and multiple myeloma were identified. The primary study outcome measure was in-hospital mortality. Inverse probability weighting-adjusted binary logistic regression was performed to identify independent predictors of in-hospital mortality. Of 2,715,807 STEMI patients included in the final analyses, 11,974 (0.4%) patients had a diagnosis of CHM. Patients with CHM were significantly older, had a higher prevalence of co-morbidities, and had a significantly higher unadjusted in-hospital mortality (14.9% vs 9.0%; p <0.001). After adjusting for co-morbidities, CHM did not independently predict a higher in-hospital mortality (odds ratio = 1.02, 95% confidence interval = 0.96 to 1.09; p = 0.461). In patients with CHM who presented with STEMI, percutaneous coronary intervention was found to be associated with a significant reduction in in-hospital mortality (odds ratio = 0.22, 95% confidence interval = 0.18 to 0.27; p <0.001) (c-statistic = 0.81). In conclusion, CHM patients presenting with STEMI should be treated with similar treatment strategies as those without CHM, including revascularization if indicated, as there appears to be a sizable outcome advantage with this approach.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. American Cancer Society. Cancer treatment and survivorship facts and figures 2014 —2015. Atlanta: Am Cancer Soc. 2014:1-48.

        • Wingard J.R.
        • Majhail N.S.
        • Brazauskas R.
        • Wang Z.
        • Sobocinski K.A.
        • Jacobsohn D.
        • Sorror M.L.
        • Horowitz M.M.
        • Bolwell B.
        • Rizzo J.D.
        • Socié G.
        Long-term survival and late deaths after allogeneic hematopoietic cell transplantation.
        J Clin Oncol. 2011; 29: 2230-2239
        • Socié G.
        • Stone J.V.
        • Wingard J.R.
        • Weisdorf D.
        • Henslee-Downey P.J.
        • Bredeson C.
        • Cahn J.Y.
        • Passweg J.R.
        • Rowlings P.A.
        • Schouten H.C.
        • Kolb H.J.
        • Klein J.P.
        Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry.
        N Engl J Med. 1999; 341: 14-21
        • Chow E.J.
        • Wong K.
        • Lee S.J.
        • Cushing-Haugen K.L.
        • Flowers M.E.
        • Friedman D.L.
        • Leisenring W.M.
        • Martin P.J.
        • Mueller B.A.
        • Baker K.S.
        Late cardiovascular complications after hematopoietic cell transplantation.
        Biol Blood Marrow Transpl. 2014; 20: 794-800
        • Santos-Gallego C.G.
        • Picatoste B.
        • Badimón J.J.
        Pathophysiology of acute coronary syndrome.
        Curr Atheroscler Rep. 2014; 16: 401
        • Jaiswal S.
        • Natarajan P.
        • Silver A.J.
        • Gibson C.J.
        • Bick A.G.
        • Shvartz E.
        • McConkey M.
        • Gupta N.
        • Gabriel S.
        • Ardissino D.
        • Baber U.
        • Mehran R.
        • Fuster V.
        • Danesh J.
        • Frossard P.
        • Saleheen D.
        • Melander O.
        • Sukhova G.K.
        • Neuberg D.
        • Libby P.
        • Kathiresan S.
        • Ebert B.L.
        Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease.
        N Engl J Med. 2017; 377: 111-121
        • Lee S.Y.
        • Hong M.K.
        • Palmerini T.
        • Kim H.S.
        • Valgimigli M.
        • Feres F.
        • Colombo A.
        • Gilard M.
        • Shin D.H.
        • Kim J.S.
        • Kim B.K.
        • Ko Y.G.
        • Choi D.
        • Jang Y.
        • Stone G.W.
        Short-term versus long-term dual antiplatelet therapy after drug-eluting stent implantation in elderly patients: a meta-analysis of individual participant data from 6 randomized trials.
        JACC Cardiovasc Interv. 2018; 11: 435-443
      2. Healthcare Cost and Utilization Project (HCUP). 2011. Agency for Healthcare Research and Quality, Rockville, MD. Available at:

        • HCUP National Inpatient Sample (NIS)
        Healthcare Cost and Utilization Project (HCUP).
        Agency for Healthcare Research and Quality, Rockville, MD2012 (Available at:)
        • Kwok C.S.
        • Tiong D.
        • Pradhan A.
        • Andreou A.Y.
        • Nolan J.
        • Bertrand O.F.
        • Curzen N.
        • Urban P.
        • Myint P.K.
        • Zaman A.G.
        • Loke Y.K.
        • Mamas M.A.
        Meta-analysis of the prognostic impact of anemia in patients undergoing percutaneous coronary intervention.
        Am J Cardiol. 2016; 118: 610-620
        • Ayoub K.
        • Marji M.
        • Ogunbayo G.
        • Masri A.
        • Abdel-Latif A.
        • Ziada K.
        • Vallurupalli S.
        Impact of chronic thrombocytopenia on in-hospital outcomes after percutaneous coronary intervention.
        JACC Cardiovasc Interv. 2018; 11: 1862-1868